Drug treatment for bleeding oesophageal varices

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 14, Issue 3, 2000, Pages 365-390

  Dagher, Lucy ^a   Patch, David ^a   Burroughs, Andrew ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Gastrointestinal haemorrhage (prevention and control); Gastrointestinal haemorrhage (therapy); Human; Hypertension; Oesophageal and gastric varices (prevention and control); Oesophageal varices (therapy); Portal (complications); Portal (therapy)

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; MOLSIDOMINE; NITRATE; OCTREOTIDE; PRAZOSIN; SEROTONIN ANTAGONIST; SOMATOSTATIN; TERLIPRESSIN; VASOACTIVE AGENT; VASOPRESSIN;

CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COLIC; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGOSCOPY; ESOPHAGUS VARICES BLEEDING; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SIDE EFFECT;

EID: 0033870882     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2000.0085     Document Type: Article

References (169)

1. Grace N D. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American Journal of Gastroenterology. 92:1997;1081-1091.
2. New England Journal of Medicine. 319:1988;983-989.
3. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology. 22:1995;332-354.
4. Robbins J, Breslow N, Greenland S. Estimators of the Mantel-Haenszel variance constant in both sparse data and large strata limiting models. Biometrics. 42:1986;311-323.
5. Der Simonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 7:1986;177-188.
6. Fogel R M, Knauer C M, Andress L L. Continuous intravenous vasopressin in active upper gastrointestinal bleeding: a placebo controlled trial. Annals of Internal Medicine. 96:1982;565-569.
7. Merigan T C, Poltkin J R, Davidson C S. Effect of intravenously administered posterior pituitary extract on haemorrhage from bleeding oesophageal varices. New England Journal of Medicine. 266:1962;134-135.
8. Conn H O, Ramsby G R, Storer E H. Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective, controlled clinical trial. Gastroenterology. 68:1975;211-221.
9. Mallory A, Schaefer J W, Cohen J R. Selective intraarterial vasopressin infusion for upper gastrointestinal tract hemorrhage: a controlled trial. Archives of Surgery. 115:1980;30-32.
10. Bosch J, Groszmann R J, Garcia-Pagan J C. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo controlled clinical trial. Hepatology. 10:1989;968.
11. Tsai Y T, Lay C S, Lai K H. Controlled trial of vasopressin plus nitroglycerin vs vasopressin alone in the treatment of bleeding esophageal varices. Hepatology. 6:1986;406-409.
12. Gimson A E, Westaby D, Hegarty J E. A randomised trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology. 6:1986;410-413.
13. Walker S, Stiehl A, Raedsch R, Kommerell B. Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. Hepatology. 6:1986;112-115.
14. Freeman J G, Cobden M D, Record C O. Placebo controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding. Journal of Clinical Gastroenterology. 11:1989;58-60.
15. Soderlund C, Magnusson I, Torngren S, Lundell L. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. Scandinavian Journal of Gastroenterology. 25:1990;622-630.
16. Levacher S, Letoumelin O, Pateron D. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet. 346:1995;865-868.
17. Freeman J G, Cobden M D, Lishaman A H, Record C O. Controlled trial of terlipressin ('glypressin') versus vasopressin in the early treatment of esophageal varices. Lancet. 2:1982;62-68.
18. Desaint B, Florent C, Levy V G. A randomized trial of triglycyl-lysine vasopressin versus lysine vasopressin in active cirrhotic variceal hemorrhage. Lebrec D, Blei A T. Vasopressin Analogs and Portal Hypertension. 1987;155-157 Libey Eurotex, Paris.
19. Lee F-Y, Tsai Y T, Lai K H. A randomized controlled study of triglycyl-vasopressin and vasopressin plus nitroglycerin in the control of acute esophageal variceal hemorrhage. Chinese Journal of Gastroenterology. 5:1988;131-138.
20. Chiu W K, Sheen I S, Liaw Y F. A controlled study of glypressin versus vasopressin in the control of bleeding from esophageal varices. Journal of Gastroenterology and Hepatology. 5:1988;549-553.
21. D'Amico G, Traina M, Vizzini G. Teripressin or vasopressin plus transdermal nitroglycerin in a treatment strategy for digestive bleeding in cirrhosis. A randomized clinical trial. Journal of Hepatology. 20:1994;206-212.
22. Colin R, Giuli N, Czernichow P. Prospective comparison of glypressin, tamponade and their association in the treatment of bleeding esophageal varices. Lebrec D, Blei A T. Vasopressin Analogs and Portal Hypertension. 1987;149-153 Libbey Eurotex, Paris.
23. Fort E, Sauterau D, Silvaine C. A randomized trial of terlipressin plus nitroglycerin vs balloon tamponade in the control of acute variceal haemorrhage. Hepatology. 11:1990;678-681.
24. Blanc P, Bories J, Desprez D. Balloon tamponade with Linton-Michel tube versus terlipressin in the treatment of acute oesophageal and gastric variceal bleeding. Journal of Hepatology. 21:1994;S133.
25. New England Journal of Medicine. 324:1991;1779-1784.
26. Brunati S, Ceriani R, Curioni R. Sclerotherapy alone vs sclerotherapy plus terlipressin vs sclerotherapy plus octreotide in the treatmetn of acute variceal haemorrhage. Hepatology. 24:1996;207A.
27. Sonneburg G E, Keller U, Perruchud A, Buchart F. Effect of somatostatin on splanchnic haemodynamics. Gastroenterology. 80:1981;5226-5232.
28. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic haemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology. 80:1981;518-525.
29. Escorsell A, Bordas J M, Ruiz del Arbol L. Randomized controlled trial of sclerotherapy vs somatostatin infusion in the prevention of early rebleeding following variceal hemorrhage in patients with cirrhosis. Journal of Hepatology. 29:1998;779-788.
30. Valenzuela J E, Schubert T, Foget R M. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology. 10:1989;958-961.
31. Burroughs A K, McCormick P A, Hughes M D. Randomised, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Gastroenterology. 99:1990;1388-1395.
32. Gotzsche P C, Gjroup I, Bonnen H. Somatostatin vs placebo in bleeding esophageal-varices - randomized trial and metaanalysis. British Medical Journal. 310:1995;1495-1498.
33. Flati G, Negro P, Flati D. Massive upper digestive hemorrhage in portal hypertension. Results of a controlled study. Revista Espanola de Enfermedades del Aparato Digestivo. 70:1986;411-414.
34. Testoni P A, Masci E, Passaretti S. Comparison of somatostatin and cimetidine in the treatment of acute esophageal variceal bleeding. Current Therapy and Research. 39:1986;759-766.
35. Kravetz D, Bosch J, Teres J. Comparison of intravenous somatostatin and vasopressin infusion in treatment of acute variceal hemorrhage. Hepatology. 4:1984;442-446.
36. Jenkins S A, Baxter J N, Corbett W. A prospective randomised controlled clinical trial comparing somatostatin and vasopressin in controlling acute variceal haemorrhage. British Medical Journal. 290:1985;275-278.
37. Bagarani M, Albertini V, Anza M. Effect of somatostatin in controlling bleeding from esophageal varices. Italian Journal of Surgical Science. 17:1987;21-26.
38. Hsia H C, Lee F Y, Tsai Y T. Comparison of somatostatin and vasopressin in the control of acute esophageal variceal hemorrhage. A randomized, controlled study. Chinese Journal of Gastroenterology. 7:1990;71-78.
39. Rodriguez-Moreno F, Santolaria F, Gles-Reimers E. A randomized trial of somatostatin vs vasopressin plus nitroglycerin in the treatment of acute variceal bleeding. Journal of Hepatology. 13:1991;S162.
40. Feu F, DelArbol L R, Banares R. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Gastroenterology. 111:1996;1291-1299.
41. Jaramillo J L, de la Mata M, Mino G. Somatostatin versus Sengstaken tube balloon tamponade for primary hemostasis of bleeding esophageal varices: a randomised pilot study. Journal of Hepatology. 12:1991;100-105.
42. Averignos A, Klonis C, Rekoumis G. A prospective randomised trial comparing somatostatin, balloon tamponade and the combination of both methods in the management of acute variceal haemorrhage. Journal of Hepatology. 13:1991;78-83.
43. Di Febo G, Siringo S, Vacirca M. Somatostatin (SMS) and urgent sclerotherapy (US) in active oesophageal variceal bleeding. Gastroenterology. 98:1990;583A.
44. Shields R, Jenkins S A, Baxter J N. A prospective randomized controlled trial comparing the efficacy of somatostatin with injection sclerotherapy in the control of bleeding esophageal-varices. Journal of Hepatology. 16:1992;128-137.
45. Planas R, Quer J C, Boix J. A prospective randomised trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding. Hepatology. 20:1994;370-375.
46. Averignos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet. 350:1997;1495-1499.
47. Signorelli S, Negrini F, Paris B. Sclerotherapy with or without somatostatin or octreotide in the treatment of acute variceal haemorrhage: our experience. Gastroenterology. 110:1996;1326A.
48. Jenkins S A, Baxter J N, Snowden S. The effects of somatostatin and SMS 201-995 on hepatic haemodynamics in patients with cirrhosis and portal hypertension. Fibrinolisis. 2:1988;48-50.
49. McCormick P A, Dick R, Siringo S. Octreotide reduces azygous blood flow in cirrhotic patients with portal hypertension. European Journal of Gastroenterology and Hepatology. 2:1990;489-492.
50. McKee R. A study of octreotide in oesophageal varices. Digestion. 45:1990;60-64.
51. Hwang S J, Lin H C, Chang C F. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. Journal of Hepatology. 16:1992;302-325.
52. Silvain C, Carpentier S, Satereau D. Terlipressin plus transdermal nitroglycerin vs octreotide in the control of acute bleeding from esophageal-varices - a multicenter randomized trial. Hepatology. 18:1993;61-65.
53. Sung J JY, Chung Sc S, Lai C W. Octreotide infusion or emergency sclerotherapy for variceal hemorrhage. Lancet. 342:1993;637-641.
54. Poo J L, Bosques F, Garduno R. Octreotide versus emergency sclerotherapy in acute variceal haemorrhage in liver cirrhosis. Gastroenterology. 110:1996;1297A.
55. Kravetz D. Octreotide vs sclerotherapy in the treatment of acute variceal bleeding. Hepatology. 96:1996;206A.
56. Jenkins S A, Shields R, Davies M. A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut. 41:1997;526-533.
57. El-Jackie A, Rowaisha I, Waked I. Octreotide vs. sclerotherapy in the control of acute variceal bleeding in schistosomal portal hypertension: a randomized trial. Hepatology. 28:1999;533A.
58. Besson I, Ingrand I, Person B. Sclerotherapy with or without octreotide for acute variceal bleeding. New England Journal of Medicine. 333:1995;555-560.
59. Signorelli S, Paris B, Negrini F. Esophageal varices bleeding: comparison between treatment with sclerotherapy alone vs sclerotherapy plus octreotide. Hepatology. 26:1997;1326A.
60. Sung J JY, Chung S S, Yung M Y. Prospective randomised study of effect of octreotide on rebleeding from esophageal varices after endoscopic ligation. Lancet. 346:1995;1666-1669.
61. Burroughs A K, Patch D. Therapeutic benefit of vaso-active drugs for acute variceal bleeding: a real pharmacological effect, or a side-effect of definitions in trials? Hepatology. 24:1996;739.
62. Burroughs A K. International Octreotide Varices Study Group. Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial failures. Hepatology. 24:1996;737-739.
63. Primignani M, Andreoni B, Carpinelli L. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal-varices - a randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 21:1995;1322-1327.
64. D'Amico G, Politi F, Morabito A. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis: a double blind, randomized pragmatic trial. Hepatology. 28:1998;1206-1214.
65. Bernard B, Cadranel J-F, Valla D. Prognostic significance of bacterial infections in bleeding cirrhotic patients: a prospective study. Gastroenterology. 108:1995;1824-1834.
66. Goulis J, Armonis A, Patch D. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 27:1998;1207-1212.
67. Bernard B, Nguyen K E, Nguyen K E. Antibiotic prophylaxis (AbP) for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding (GB): a meta-analysis. Hepatology. 29:1999;1655-1661.
68. Grace N D, Groszmann R J, Garcia-Tsao G. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology. 28:1998;868-880.
69. Pagliaro L, D'Amico G, Pasta L. Portal hypertension in cirrhosis: natural history. Bosch J, Groszmann R J. Portal Hypertension: Pathophysiology and Treatment. 1994;72-92 Blackwell Scientific, Cambridge.
70. Vorobioff J, Groszmann R J, Picabea E. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 111:1996;701-709.
71. Groszmann R J, Bosch J, Grace N D. Hemodynamic events in a prospective randomized trial of propranol versus placebo in the prevention of the 1st variceal hemorrhage. Gastroenterology. 99:1990;1401-1407.
72. Feu F, Garcia-Pagan J C, Bosch J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet. 346:1995;1056-1059.
73. McCormick A, Patch D, Greenslade L. Clinical versus haemodynamic response to drugs in portal hypertension. Journal of Hepatology. 28:1998;1015-1019.
74. Cerbelaud P, Lavignolle A, Perrin D. Propranolol et prevention des recidives de rupture de varice oesophagienne du cirrhotique. Gastroenterologie Clinique et Biologique. 18:1986;A10.
75. Burroughs A K, Jenkins W J, Sherlock S. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. New England Journal of Medicine. 309:1983;1539-1542.
76. Colman J, Jones P, Finch C, Dudley F. Propranolol in the prevention of variceal hemorrhage in alcoholic cirrhotic patients. Hepatology. 8:1990;1395A.
77. Colombo M, de Franchis R, Tomamsini M. Beta-blockade prevents recurrent gastrointestinal-bleeding in well-compensated patients with alcoholic cirrhosis - a multicenter randomized controlled trial. Hepatology. 9:1989;433-438.
78. Garden O J, Mills P R, Birnie G G. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic-patients - a controlled trial. Gastroenterology. 98:1990;185-190.
79. Gatta A, Merkel C, Sacerdoti D. Nadolol for prevention of variceal rebleeding in cirrhosis - a controlled clinical-trial. Digestion. 37:1987;22-28.
80. Kobe E, Schentke K U. Unsichere rezidivprophylaxe von osophagusvarizenblutungen durch Propranolol bei Leberzirrhotikern: eine prospektive kontrolliertr studie. Zeitschrift Fur Klinische Medizin-Zkm. 42:1987;507-510.
81. Lebrec D, Poynard T, Bernuau J. A randomized controlled-study of propranolol for prevention of recurrent gastrointestinal-bleeding in patients with cirrhosis - a final report. Hepatology. 4:1984;355-358.
82. Queuniet A M, Czernichow P, Lerebours E. Controlled trial of propranolol for the prevention of recurrent gastrointestinal-bleeding in patients with cirrhosis. Gastroenterologie Clinique et Biologique. 11:1987;41-47.
83. Rossi V, Cales P, Burtin P. Prevention of recurrent variceal bleeding in alcoholic cirrhotic-patients - prospective controlled trial of propranolol and sclerotherapy. Journal of Hepatology. 12:1991;283-289.
84. Sheen I S, Chen T Y, Liaw Y F. Randomized controlled-study of propranolol for prevention of recurrent esophageal-varices bleeding in patients with cirrhosis. Liver. 9:1989;1-5.
85. Villeneuve J P, Pomier-Layrargues G, Infanterivard C. Propranolol for the prevention of recurrent variceal hemorrhage - a controlled trial. Hepatology. 6:1986;1239-1243.
86. Bernard B, Lebrec D, Mathurin P. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology. 25:1997;63-70.
87. Vinel J P, Monnin J L, Combis J M. Evaluation of molsidomine - a vasodilator with antianginal properties in patients with alcoholic cirrhosis. Hepatology. 11:1990;239-242.
88. Vorobioff J, Garcia-Tsao G, Groszmann R J. Long term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker in portal hypertensive patients. Hepatology. 6:1989;88-91.
89. Nevens F, Lijnen P, VanBilloen H, Fevery J. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology. 23:1996;1047-1052.
90. Alexandrino P T, Alves M M, Correia J P. Propranolol or endoscopic sclerotherapy in the prevention of recurrence of variceal bleeding - a prospective, randomized controlled trial. Journal of Hepatology. 7:1988;175-185.
91. Andreani T, Poupon R E, Balkau B J. Efficacite comparée du propranolol et des scleroses endoscopiques du varices oesophagiennes dans la prevention des recidives d'hemorragies digestives au cours des cirrhoces. Etude controlee. Gastroenterologie Clinique et Biologique. 15 (supplement 2):1991;A215.
92. Dasarathy S, Dwivedi M, Bhargava D K. A prospective randomized trial comparing repeated endoscopic sclerotherapy and propranolol in decompensated (Child class-b and class-c) cirrhotic-patients. Hepatology. 16:1992;89-94.
93. Dollet J M, Champigneulle B, Patris A. Endoscopic sclerotherapy versus oral propranolol after variceal hemorrhage in cirrhosis - results of a 4-year prospective randomized trial. Gastroenterologie Clinique et Biologique. 12:1988;234-239.
94. Fleig W E, Stange E F, Schonborn W. Final analysis of a randomized trial of propranolol (P) vs sclerotherapy (Eps) for the prevention of recurrent variceal hemorrhage in cirrhosis. Hepatology. 8:1988;1220.
95. Liu J D, Jeng Y S, Chen P H. Endoscopic injection sclerotherapy and propranolol in the prevention of recurrent variceal bleeding. Gastroenterology World Congress Abstract Book. 1990;. p. FP1181.
96. Martin T, Taupignon A, Lavignolle A. Prevention of recurrent bleeding in patients with cirrhosis - results of a controlled trial of propranolol versus endoscopic sclerotherapy. Gastroenterologie Clinique et Biologique. 15:1991;833-837.
97. Teres J, Bosch J, Bordas J M. Endoscopic sclerotherapy (Es) Vs propranolol (Pr) in the elective treatment of variceal bleeding - preliminary-results of a randomized controlled clinical-trial. Journal of Hepatology. 5:1987;S210.
98. Westaby D, Polson R J, Gimson A E. A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variceal bleeding. Hepatology. 11:1990;353-359.
99. Villanueva C, Balanzo J, Novella M T. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. New England Journal of Medicine. 334:1996;1624-1629.
100. Minyana J, Gallego A, Sola Vera J. Endoscopic ligation versus nadolol plus isosorbide-5-mononitrate for the prevention of variceal rebleeding. A prospective randomized trial. Hepatology. 30:1999.
101. Patch D, Goulis G, Gerunda C. A randomised controlled trial comparing wedge pressure guided medical therapy (MT) against variceal bleeding (VB) in the secondary prevention of variceal haemorrhage. Gut. 2000.
102. Westaby D, Melia W, Hegarty J E. Use of propranolol to reduce the rebleeding rate during injection sclerotherapy prior to variceal obliteration. Hepatology. 6:1986;673-675.
103. Jensen L S, Kraup N. Propranolol in prevention of rebleeding from esophageal-varices during the course of endoscopic sclerotherapy. Scandinavian Journal of Gastroenterology. 24:1989;339-345.
104. Lundell L, Leth R, Lind T. Evaluation of propranolol for prevention of recurrent bleeding from esophageal-varices between sclerotherapy sessions. Acta Chirurgica Scandinavica. 156:1990;711-715.
105. Vinel J P, Lamouliattte H, Cales P. Propranolol reduces the rebleeding rate during endoscopic sclerotherapy before variceal obliteration. Gastroenterology. 102:1992;1760-1763.
106. Avgerinos A, Rekoumis G, Klonis C. Propranolol in the prevention of recurrent upper gasatrointestinal-bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy - a randomized controlled trial. Journal of Hepatology. 19:1993;301-311.
107. Acharya S K, Dasarathy S, Saksena S, Pande J N. A prospective randomized study to evaluate propranolol in patients undergoing long-term endoscopic sclerotherapy. Journal of Hepatology. 19:1993;291-300.
108. Vickers C, Rhodes J, Chesner I. Prevention of rebleeding from esophageal-varices - 2-year follow-up of a prospective controlled trial of propranolol in addition to sclerotherapy. Journal of Hepatology. 21:1994;81-87.
109. El-Sayed S S, Shiha G, Hamid M. Sclerotherapy versus sclerotherapy and propranolol in the prevention of rebleeding from oesophageal varices: a randomised study. Gut. 38:1996;770-774.
110. Bertoni G, Fornaciari G, Beltrami M. Nadolol for prevention of variceal rebleeding during the course of endoscopic injection sclerotherapy - a randomized pilot-study. Journal of Clinical Gastroenterology. 12:1990;364-365.
111. Gerunda G E, Neri D, Zangrandi F. Nadolol does not reduce early rebleeding in cirrhotics undergoing endoscopic variceal sclerotherapy (Evs) - a multicenter randomized controlled trial. Hepatology. 12:1990;988.
112. Villanueva C, Martinez F J, Torras X. Nadolol as an adjuvant to sclerotherapy of esophageal varices for prevention of recurrent hemorrhaging. Revista Espanola de Enfermedades Digestivas. 86:1994;499-504.
113. Bertoni G, Sassatelli R, Fornaciari G. Oral isosorbide-5-mononitrate reduces the rebleeding rate during the course of injection sclerotherapy for esophageal-varices. Scandinavian Journal of Gastroenterology. 29:1994;363-370.
114. Perezayuso R M, Pique J M, Bosch J. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet. 337:1991;1431-1434.
115. Andreani T, Poupon R E, Balkau B J. Preventive therapy of 1st gastrointestinal bleeding in patients with cirrhosis - results of controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology. 12:1990;1413-1419.
116. Bendsten F, Christensen E, Hardt F. Prophylaxis of 1st hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients - a randomized multicentric trial. Hepatology. 14:1991;1024.
117. Strauss E, Desa M G, Albano A. A randomized controlled trial for the prevention of the 1st upper gastrointestinal bleeding due to portal hypertension in cirrhosis - sclerotherapy or propranolol versus control groups. Hepatology. 8:1988;1395.
118. Pascal J P, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. New England Journal of Medicine. 317:1987;856-861.
119. Pasta L. Propranolol prevents 1st gastrointestinal bleeding in non ascitic cirrhotics patients - a final report of a multicenter randomized trial. Journal of Hepatology. 9:1989;75-83.
120. Conn H O, Grace N D, Bosch J. Propranolol in the prevention of the 1st hemorrhage from esophagogastric varices - a multicenter randomized clinical trial. Hepatology. 13:1991;902-912.
121. Ideo G, Bellati G, Fesce E, Grimoldi D. Nadolol can prevent the 1st gastrointestinal bleeding in cirrhotics - a prospective, randomized study. Hepatology. 8:1988;6-9.
122. Lebrec D, Poynard T, Capon J P. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis - a randomized trial. Journal of Hepatology. 7:1988;118-125.
123. Lebrec D. A discussion of how terlipressin limits mortality in cases of bleeding oesophageal varices. European Journal of Gastroenterology and Hepatology. 10:1998;549-552.
124. Poynard T, Cales P, Pasta L. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices - an analysis of data and prognostic factors in 589 patients from four randomized clinical trials. New England Journal of Medicine. 324:1991;1532-1538.
125. Grace N D, Conn H O, Groszmann R J. Propranolol for the prevention of the 1st esophageal variceal hemorrhage - a life time commitment. Hepatology. 12:1990;407.
126. Merkel C, Marin R, Enzo E. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'Ipertensione portale (GTIP). Lancet. 348:1996;1677-1681.
127. Angelico M, Carli L, Piat C. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long term survival in cirrhosis. Gastroenterology. 113:1997;1632-1639.
128. De B K, Ghoshal C U, Das T. Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial. Journal of Gastroenterology and Hepatology. 14:1999;220-224.
129. Lui H, Stanley A J, Forrest E H, Jalan R. Primary prophylaxis of variceal haemorrhage: a randomized controlled trial comparing band ligation, propranolol and isosorbide mononitrate. Hepatology. 30:1999.
130. Sarin S K, Lamba G S, Kumar M. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. New England Journal of Medicine. 340:1999;988-993.
131. Burroughs A K, Patch D. Primary prevention of bleeding from esophageal varices. New England Journal of Medicine. 340:1999;1033-1035.
132. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin and nitric oxide. Hepatology. 25:1997;2-5.
133. Shah V, Garcia-Cardena G, Sessa W, Groszmann R J. The hepatic circulation in health and disease: report of a single-topic symposium. Hepatology. 27:1998;279-288.
134. Sogni P, Moreau R, Gomola A. Beneficial hemodynamic effects of bosentan, a mixed ETa and ETb receptor antagonist, in portal hypertensive rats. Hepatology. 28:1998;655-659.
135. Gupta T K, Chung M K, Toruner M, Groszmann R J. Endothelial dysfunction in the intrahepatic microcirculation of the cirrhotic rat. Hepatology. 28:1998;926-931.
136. Gentilini P, Romanelli R G, La Villa G. Effects of low dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology. 104:1993;588-594.
137. Ibarra F R, Afione C, Garzon D. Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis. European Journal of Clinical Pharmacology. 43:1992;477-482.
138. Pariente A E, Bataille C, Bercoff E. Acute effects of captopril on systemic and renal hemodynamic and on renal function in cirrhotic patients with ascites. Gastroenterology. 88:1985;1255-1259.
139. Svoboda P, Ochmann J, Kantrova I. Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic hemodynamics in portal hypertension. Hepatogastroenterology. 39:1992;549-552.
140. Chiang H T, Cheng J S, Lin M. Hemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. Journal of Gastroenterology and Hepatology. 10:1995;256-260.
141. Schneider A W, Kalk F J, Klein C P. Effect of Losartan, an angiotensin II receptor antagonist on portal pressure in cirrhosis. Hepatology. 29:1999;334-339.
142. Debernardi-Venon D, Barletti C, Marzano A. Efficacy of Irbestartan, an angiotensin II receptor selective antagonist, in the treatment of portal hypertension. Hepatology. 30:1999;219A.
143. Garcia-Tsao G. Angiotensin II receptor antagonist in the pharmacological therapy: a caution. Gastroenterology. 117:1999;740-742.
144. Albillos A, Liedo J L, Rossi I. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology. 109:1995;1257-1265.
145. Frishman W H. Drug therapy: carvedilol. New England Journal of Medicine. 339:1998;1759-1765.
146. Forrest E H, Bouchier I A, Hayes P C. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. Journal of Hepatology. 25:1996;909-915.
147. Stanley A J, Therapondos G, Helmy A, Hayes P C. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. Journal of Hepatology. 30:1999;479-484.
148. Banares R, Moitinho E, Piqueras B. Carvedilol, a new non-selective beta-blocker with intrinsic anti-alpha1 adrenergic activity, has a greater portal hypotensive effects than propranolol in patients with cirrhosis. Hepatology. 30:1999;79-83.
149. Albillos A, Banares R, Barrios G. Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects. Gastroenterology. 102:1992;248-254.
150. Roulot D, Moreau R, Gaudin C. Long-term sympathetic and hemodynamic responses to clonidine in patients with cirrhosis and ascites. Gastroenterology. 102:1992;1309-1318.
151. Atkinsons M. The effects of diuretics on portal venous pressure. Lancet. 2:1959;819-823.
152. Cereda J M, Roulot D, Braillon A. Reduction in portal pressure by acute administration of furosemide in patients with alcoholic cirrhosis. Journal of Hepatology. 9:1989;246-251.
153. Okumura H, Aramaki T, Katsuta Y. Reduction in hepatic vein pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. American Journal of Gastroenterology. 86:1991;46-52.
154. Garcia-Pagan J C, Salmeron J M, Feu F. Effects of low sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology. 19:1994;1095-1099.
155. Sugano S, Gusuki T, Nishio M. Chronic splanchnic hemodynamic effects of low dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis. Digestive Diseases and Sciences. 42:1997;529-535.
156. Lin H C, Yang M CM, Huang Y T. The hemodynamic effect of AT-112, an analog of ketaserin, in portal hypertensive rats. Pharmacology. 54:1997;16-23.
157. Hadengue A, Lee S S, Moreau R. Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: possible role of serotonergic mechanism in portal hypertension. Hepatology. 7:1987;644-647.
158. Mastai R, Giroux L, Semret M, Huet P M. Ritanserin decreases portal pressure in conscious and unrestrained cirrhotic rats. Gastroenterology. 98:1990;145.
159. Nevens F, Pizcueta M P, Fernandez M. Effects of ritanserin, a specific S2-serotoninergic antagonist, on portal pressure and splanchnic haemodynamics in portal hypertensive rats. Hepatology. 14:1991;1174-1178.
160. Goulis J, Patch D, Burroughs A K. Bacterial infection in the pathogenesis of variceal bleeding. Lancet. 353:1999;139-142.
161. Berck P D, Sacks H S. Assessing the quality of randomized controlled trials: quality of design is not only the relevant variable. Hepatology. 30:1999;1332-1334.
162. Kjaergard L L, Bikilova D, Gluud C. Randomized clinical trials in hepatology: prediction of quality. Hepatology. 30:1999;1134-1138.
163. de Franchis R. Developing consensus in portal hypertension. Journal of Hepatology. 25:1996;390-394.
164. Hepatology. 26:1997;249A.
165. Loperfido S, Godena F, Tosolini G. Somatostatin in the treatment of hemorrhagic esophagogastric varices. Controlled clinical trial in comparison with ranitidine. Recenti Progressi in Medicina. 78:1987;82-86.
166. Cardona C, Vida F, Balanzo J. Efficacia terapeutica de la somatostatina versus vasopressina mas nitroglycerina en la hemorragia activa por varices esofagogastrica. Gastroenterology and Hepatology. 12:1989;30-34.
167. Saari A, Kivilaasko E, Inberg M. Comparison of somatostatin and vasopressin in bleeding esophageal varices. American Journal of Gastroenterology. 85:1990;804-807.
168. Walker S, Kreichgauer H P, Bode J C. Terlipressin (glypressin) versus somatostatin in the treatment of bleeding esophageal varices - final report of a placebo-controlled, double-blind study. Zeitschrift für Gastroenterologie. 34:1996;692-698.
169. Shiha G, El-Sayed S. Gastric variceal ligation: a new technique. Gastrointestinal Endoscopy. 49:1999;437-441.